Primary cutaneous anaplastic large cell lymphoma associated with vascular endothelial growth factor arising from a burn scar

Journal of the American Academy of Dermatology

Volumn 57, Issue 5 SUPPL., 2007, Pages

  Morihara, Kiyoshi ^a,b   Takenaka, Hideya ^a   Morihara, Toru ^a   Kishimoto, Saburo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Fukuchiyama City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; ENDOTHELIAL CELL GROWTH FACTOR;

ANAMNESIS; ARTICLE; BURN SCAR; CASE REPORT; CLINICAL FEATURE; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LARGE CELL LYMPHOMA; LYMPHOCYTE; PRIORITY JOURNAL; SKIN CANCER; SKIN EXAMINATION;

ANTIGENS, CD30; BURNS; CICATRIX; ERYTHEMA; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SKIN; SKIN NEOPLASMS; SKIN ULCER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35148850618     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.10.018     Document Type: Article

References (7)

1. Stein H., Foss H.D., Durkop H., Marafioti T., Delsol G., Pulford K., et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96 (2000) 3681-3695
2. Fletcher C.L., Orchard G.E., Hubbard V., Whittaker S.J., Edelson R.L., and Russell-Jones R. CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol 140 (2004) 449-454
3. Kobayashi M., Kobayashi H., Herndon D.N., Pollard R.B., and Suzuki F. Burn-associated Candida albicans infection caused by CD30+ type 2 T cells. J Leukoc Biol 63 (1998) 723-731
4. Yeung C.K., Ma S.Y., Chan H.H., Trendell-Smith N.J., and Au W.Y. Primary CD30+ve cutaneous T-cell lymphoma associated with chronic burn injury in a patient with longstanding psoriasis. Am J Dermatopathol 26 (2004) 394-396
5. Shimamoto T., Hayashi S., Ando K., Yguchi M., Miyazawa K., Kimura Y., et al. Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy. Am J Hematol 66 (2001) 49-52
6. Salven P., Teerenhovi L., and Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90 (1997) 3167-3172
7. Wang E.S., Teruya-Feldstein J., Wu Y., Zhu Z., Hicklin D.J., and Moore M.A. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 104 (2004) 2893-2902